Apixaban in Thrombocytopenia

Summary

This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low number of platelets in the blood). Investigators are also looking to see if participants on this treatment have fewer bleeding episodes. The name of the study drug involved in this study is: -Apixiban (a type of anticoagulant)

Timeline

Start

2025-02-28

Primary completion

2027-07-01

Completion

2029-07-01

Drugs

Indications